European journal of oncology nursing : the official journal of European Oncology Nursing Society · 2026
Acceptance and commitment therapy for psychosomatic outcomes and quality of life in adults with cancer: Systematic review and meta-analysis.
СтатьяСистематический обзорМетаанализНазвание и аннотация: Перевод в очереди
Обработка статьи · этапы, ошибки и управление
Загрузка состояния…
Ошибки и ограничения
История · было → стало
Состояние обновляется каждые 5 секунд, пока блок открыт. Процент показывается только там, где известен объём работы. Пауза останавливает продолжение этапа; текущий запрос к источнику может завершиться.
Kang Zhixuan, Xu Yijia, Li Huiyuan, Arbing Rachel, Chen Wei-Ti, Ke Xi, Huang Feifei
Аннотация
PURPOSE: Acceptance and commitment therapy (ACT) is widely used for cancer patients, yet its effects are not well understood with respect to psychosomatic outcomes and quality of life (QoL). This review aims to explore the effects of ACT on the psychosomatic outcomes and QoL of cancer patients.
METHODS: Eleven electronic databases were searched from inception to December 2025. Two authors independently extracted the data. RevMan 5.4 was used for data analysis and RoB 2.0 and GRADE were used for quality assessment.
RESULTS: Forty studies were included, 30 of which were eligible for meta-analysis. The meta-analysis revealed that compared with the control, ACT used alone had significant effects on hope [SMD = 3.01, 95% CI (0.69, 5.34)], psychological flexibility [SMD = -1.42, 95% CI (-1.96, -0.87)], psychological distress [SMD = -0.79, 95% CI (-1.45, -0.13)], anxiety [SMD = -0.92, 95% CI (-1.70, -0.14)], depressive symptoms [SMD = -0.95, 95% CI (-1.50, -0.39)], fatigue [SMD = -0.81, 95% CI (-1.55, -0.06)] and QoL [SMD = 1.07, 95% CI (0.14, 2.00)] in cancer patients. ACT used in combination can relieve depressive symptoms [SMD = -2.04, 95% CI (-2.44, -1.65)], anxiety [SMD = -2.10, 95% CI (-2.78, -1.41)] and fatigue [SMD = -2.49, 95% CI (-2.90, -2.08)].
CONCLUSION: ACT can improve hope, psychological flexibility, psychological distress, anxiety, depressive symptoms and the QoL of cancer patients. Future studies should expand sample sizes and optimize designs to advance research with cancer patients.
METHODS: Eleven electronic databases were searched from inception to December 2025. Two authors independently extracted the data. RevMan 5.4 was used for data analysis and RoB 2.0 and GRADE were used for quality assessment.
RESULTS: Forty studies were included, 30 of which were eligible for meta-analysis. The meta-analysis revealed that compared with the control, ACT used alone had significant effects on hope [SMD = 3.01, 95% CI (0.69, 5.34)], psychological flexibility [SMD = -1.42, 95% CI (-1.96, -0.87)], psychological distress [SMD = -0.79, 95% CI (-1.45, -0.13)], anxiety [SMD = -0.92, 95% CI (-1.70, -0.14)], depressive symptoms [SMD = -0.95, 95% CI (-1.50, -0.39)], fatigue [SMD = -0.81, 95% CI (-1.55, -0.06)] and QoL [SMD = 1.07, 95% CI (0.14, 2.00)] in cancer patients. ACT used in combination can relieve depressive symptoms [SMD = -2.04, 95% CI (-2.44, -1.65)], anxiety [SMD = -2.10, 95% CI (-2.78, -1.41)] and fatigue [SMD = -2.49, 95% CI (-2.90, -2.08)].
CONCLUSION: ACT can improve hope, psychological flexibility, psychological distress, anxiety, depressive symptoms and the QoL of cancer patients. Future studies should expand sample sizes and optimize designs to advance research with cancer patients.